This activity is intended for cardiologists, neurologists, hematology and oncology specialists, and nurses.
The goal of this activity is to improve the recognition, diagnosis, and management of cardiac amyloidosis.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 3/28/2019
Valid for credit through: 3/28/2020
processing....
6MWT = 6-minute walk-test
AA = secondary amyloidosis
AE = adverse event
AL amyloidosis = immunoglobulin light-chain amyloidosis
AL amyloid = immunoglobulin light-chain amyloid
AS = aortic stenosis
ATTR = transthyretin-related amyloidosis
ATTRmt = transthyretin-mutant amyloidosis
ATTRwt = transthyretin-wild type amyloidosis
AV = atrioventricular
BNP = brain natriuretic peptide
CA = cardiac amyloidosis
CM = cardiomyopathy
Cr = creatinine
CT = carpal tunnel
cTnT = cardiac troponin T
CV = cardiovascular
DPD = 3,3-diphosphono-1,2-propanodicarboxylic acid
ECG = electrocardiographic; electrocardiogram
EF = ejection fraction
FLC = free light chain
FLC-diff = difference between involved and uninvolved light chain
hATTR = hereditary transthyretin-related amyloidosis
H:CL = heart:contralateral
HCM = hypertrophic cardiomyopathy
HDP =
99mTc-labeled hydroxymethylene diphosphonate
HF = heart failure
HFpEF = heart failure with preserved ejection fraction
HTN = hypertension
IF = immunofluorescence
KCCQ-OS = Kansas City Cardiomyopathy Questionnaire–Overall Summary
LGE = late gadolinium enhancement
LV = left ventricular
LVEF = left ventricular ejection fraction
LVH = left ventricular hypertrophy
Mo = month
MRI = magnetic resonance imaging
MWT = maximal wall thickness
NIS = Neuropathy Impairment Score
NNT = number needed to treat
NSAID = nonsteroidal anti-inflammatory drug
NT-proBNP = N-terminal pro-B-type natriuretic peptide
NYHA = New York Heart Association
PYP = pyrophosphate
RNAi = RNA interference
SPIE = serum protein immunoelectrophoresis
TAVR = transcatheter aortic valve replacement
THOAS = Transthyretin Amyloid Outcome Survey
TTR = transthyretin
UPIE = urine protein immunoelectrophoresis
« Return to: Amyloidosis in Cardiology Practice: A Race Against Time |